Internal Medicine, Cardiovascular Disease · Tarzana, CA
NPI
1356360887
Since 2006
Specialty
Internal Medicine, Cardiovascular Disease
Code 207RC0000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
18370 Burbank Blvd, 401
Tarzana, CA, 91356
Phone (818) 996-4100
Groups this clinician bills Medicare through
Medicare paid, 2024
$6.7M
370,182 services
Medicare patients, 2024
1,372
Average age 76
Drug cost, 2024
$8.6M
33,117 prescriptions
Company payments, 2025
$4,035
From 26 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Afshine A Emrani was code J1306 (injection, inclisiran, 1 mg), 155,916 times for 312 patients. In total Afshine A Emrani billed 370,182 services in 134 codes, and Medicare paid $6.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2017-01-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1306 Injection, inclisiran, 1 mg | Office | 155,916 | 312 | $9.52 | $1.5M |
| J0897 Injection, denosumab, 1 mg | Office | 17,820 | 182 | $20.70 | $369K |
| J1071 Injection, testosterone cypionate, 1 mg | Office | 7,800 | 14 | $0.02 | $152 |
| 99213 Office E&M - Established | Office | 4,064 | 1,208 | $77.25 | $314K |
| 80076 Clinical Chemistry | Office | 3,466 | 1,255 | $7.99 | $28K |
| 82550 Clinical Chemistry | Office | 3,459 | 1,254 | $6.37 | $22K |
| 85025 Blood Count | Office | 3,455 | 1,255 | $7.60 | $26K |
| 84550 Clinical Chemistry | Office | 3,451 | 1,256 | $4.42 | $15K |
| 84480 Clinical Chemistry | Office | 3,427 | 1,255 | $13.88 | $48K |
| 84439 Clinical Chemistry | Office | 3,424 | 1,255 | $8.83 | $30K |
| 84443 Clinical Chemistry | Office | 3,422 | 1,255 | $16.44 | $56K |
| 80061 Clinical Chemistry | Office | 3,417 | 1,255 | $13.09 | $45K |
| 83036 Blood Count | Office | 3,406 | 1,255 | $9.51 | $32K |
| 83880 Clinical Chemistry | Office | 3,395 | 1,252 | $38.40 | $130K |
| 84484 Clinical Chemistry | Office | 3,379 | 1,251 | $12.20 | $41K |
By year: 2022 $3.0M for 124,466 services; 2023 $5.1M for 234,015 services; 2024 $6.7M for 370,182 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 80076 Clinical Chemistry | 3,466 | 1,255 | $7.99 | $28K |
| 82550 Clinical Chemistry | 3,459 | 1,254 | $6.37 | $22K |
| 85025 Blood Count | 3,455 | 1,255 | $7.60 | $26K |
| 84550 Clinical Chemistry | 3,451 | 1,256 | $4.42 | $15K |
| 84480 Clinical Chemistry | 3,427 | 1,255 | $13.88 | $48K |
| 84439 Clinical Chemistry | 3,424 | 1,255 | $8.83 | $30K |
| 84443 Clinical Chemistry | 3,422 | 1,255 | $16.44 | $56K |
| 80061 Clinical Chemistry | 3,417 | 1,255 | $13.09 | $45K |
| 83036 Blood Count | 3,406 | 1,255 | $9.51 | $32K |
| 83880 Clinical Chemistry | 3,395 | 1,252 | $38.40 | $130K |
Medicare prescription drug claims, 2024
In 2024, the drug Afshine A Emrani prescribed most often to Medicare patients was Vascepa (Icosapent Ethyl), with 1,347 prescriptions and refills. In total Afshine A Emrani wrote 33,117 Medicare prescriptions that cost $8.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Vascepa Icosapent Ethyl | 1,347 | 1,695 | 250 | $572K |
| Rosuvastatin Calcium Generic | 1,079 | 2,345 | 262 | $13K |
| Amlodipine Besylate Generic | 1,034 | 2,039 | 243 | $4,013 |
| Atorvastatin Calcium Generic | 915 | 2,179 | 234 | $6,155 |
| Repatha Sureclick Evolocumab | 895 | 1,115 | 127 | $605K |
| Icosapent Ethyl Generic | 886 | 1,153 | 211 | $181K |
| Metoprolol Succinate Generic | 885 | 1,826 | 216 | $8,853 |
| Olmesartan Medoxomil Generic | 865 | 1,792 | 210 | $13K |
| Levothyroxine Sodium Generic | 727 | 1,639 | 162 | $6,764 |
| Metformin Hcl Generic | 638 | 1,292 | 152 | $2,907 |
| Clopidogrel Clopidogrel Bisulfate | 632 | 1,147 | 128 | $4,315 |
| Escitalopram Oxalate Generic | 620 | 1,265 | 170 | $5,680 |
| Dexlansoprazole Dr Dexlansoprazole | 602 | 850 | 107 | $139K |
| Carvedilol Generic | 562 | 1,013 | 109 | $2,639 |
| Eliquis Apixaban | 557 | 830 | 94 | $482K |
Brand drugs: 10,094 claims; generic drugs: 22,868 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Afshine A Emrani $4,035 ($4,035 in general payments such as food, travel and fees) from 26 companies. The largest payer was Amgen Inc. with $1,078.
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. AMGN | 22 | $1,078 |
| Abbvie Inc. ABBV | 26 | $794 |
| Esperion Therapeutics, Inc. ESPR | 13 | $253 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $220 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $199 |
| GlaxoSmithKline, LLC. GSK | 9 | $198 |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $197 |
| Regeneron Healthcare Solutions, Inc. REGN | 2 | $151 |
| Novo Nordisk Inc NVO | 5 | $130 |
| Radius Health, Inc. | 3 | $91.89 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.